Enterprise Value

547.4M

Cash

823M

Avg Qtr Burn

-22.45M

Short % of Float

10.49%

Insider Ownership

28.85%

Institutional Own.

27.32%

Qtr Updated

06/30/23


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Izokibep Details
Axial spondyloarthritis

Phase 3

Initiation

Izokibep Details
Psoriatic arthritis

Phase 2/3

Data readout

Phase 2/3

Update

Izokibep Details
Hidradenitis suppurativa

Phase 2/3

Update

SLRN-517 Details
Allergy, Inflammatory disease, KIT/Mast cell diseases

Phase 1/2

Data readout

Lonigutamab Details
Thyroid Eye Disease

Phase 1/2

Data readout